DYN (Dyne Therapeutics) Short Interest

View and export this data going back to 2020. Start your Free Trial

What is Dyne Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Dyne Therapeutics's Short Interest

For the Biotechnology subindustry, Dyne Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dyne Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Dyne Therapeutics's Short Interest falls into.

Dyne Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyne Therapeutics Inc (NAS:DYN) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

1560 Trapelo Road, Waltham, MA, USA, 02451

Website

https://www.dyne-tx.com

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Executives

Richard William Scalzo	officer: See Remarks	25 ALBERTA LANE, HOLLISTON MA 01746
Oxana Beskrovnaya	officer: See Remarks	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Dirk Kersten	director, 10 percent owner	C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC
Carlo Incerti	director	FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC
Jason P Rhodes	director, 10 percent owner	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Susanna Gatti High	officer: Chief Operating Officer	75 LORIMER ROAD, BELMONT MA 02141
Wildon Farwell	officer: Chief Medical Officer	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451
Jonathan Mcneill	officer: See Remarks	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Joshua T Brumm	director, officer: See Remarks	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Atlas Venture Opportunity Fund I, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Romesh Subramanian	10 percent owner, officer: Chief Scientific Officer	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451